Is 1244.HK overvalued or undervalued?

1244.HK currently has a P/E ratio of -2.86. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy 3D Medicines Inc. stock?

3D Medicines Inc. trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 1244.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 1244.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 1244.HK to protect their purchasing power. Because 1244.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 1244.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 1244.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 1244.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks1244.HK

3D Medicines Inc.

HK$2.39+HK$0.08+3.46%

HKSE / HKD

Market cap

HK$588M

P/E

-2.9

EPS (TTM)

HK$-0.10

Dividend yield

0.00%

Beta

0.25

1Y return

-66.39%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$9M2021

$82M2022

$89M2023

$61M2024

$51M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.33Low
Current ratio1.21
Cash ratio0.33
Net margin-48.5%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

1244.HK-2.9
Healthcare sector median26.8
S&P 50022.0

Trades about 111% below its sector, cheaper than its peers on earnings.

Ratios

PEG0.63
Price to book0.95
EPS (TTM)HK$-0.10
Payout ratio0%
FCF yield-12.75%

Range & risk

HK$1.82HK$6.95

Trading in the lower third of its 52-week band

Beta0.25

Profile

What 3D Medicines Inc. actually does

Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.

CEO

Zhaolong Gong

Employees

162

Headquarters

Qingdao, SD

Founded

2022-12-15

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 1244.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

1244.HK has a beta of 0.25, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

3D Medicines Inc.